NEW YORK, April 30, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) between August 13, 2014 and March 12, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Utah. To get more information go to:
http://www.zlk.com/pslra-d/myriad-genetics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
Continental AG Shares Jump After Q1 Profit Beats Expectations
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 



